Certara provides biosimulation software and drug-development services that help pharmaceutical and biotech companies model how drugs behave in the body. Flagship platforms such as Simcyp and Phoenix support model-informed drug development, regulatory submissions, and clinical trial design. Its customers are primarily life-science R&D organizations seeking to reduce development risk and improve dosing and efficacy decisions with quantitative science.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 92.4 | — | -2 | — |
| Q3 2025 | 104.6 | — | 1.5 | — |
| Q4 2025 | 103.7 | — | -5.9 | — |
| Q1 2026 | 106.9 | — | -8.8 | — |
| Q2 2026 | 93.3 | 1% | -55.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Keel Infrastructure Corp. (KEEL), Westamerica Bancorporation (WABC), Absci Corporation (ABSI), Amalgamated Financial Corp. (AMAL), Arhaus, Inc. (ARHS), Burke & Herbert Financial Services Corp. (BHRB)